Additionally, emodin attenuates the high metastatic potential to the liver in the context of obesity and hyperlipidemia through modulation of the AKT and ERK signaling pathways, involving interaction with CSNK2A1 in breast cancer [471]. Here, AKT1 is linked to obesity disorder.